Trial · NCT06856265
Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06856265, Not applicable, Not yet recruiting, Shanghai Chest Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Trials, record NCT06856265. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06856265
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- NCT number
- NCT06856265
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Shanghai Chest Hospital
- Conditions
- Obstructive Hypertrophic Cardiomyopathy, Mavacamten, Radiofrequency Ablation
- Interventions
- radiofrequency ablation, Mavacamten
- First posted
- 2025-03-04
- Last updated
- 2025-03-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Valsalva LVOT peak gradient from baseline to week 30, as determined by Doppler echocardiography. | from baseline to week 30 | Change in Valsalva LVOT peak gradient from baseline to week 30, as determined by Doppler echocardiography. |
| Secondary | The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 30mmHg. | At week 30 | The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 30mmHg. |
| Secondary | The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 50 mm Hg. | At week 30 | The proportion of patients at week 30 with a Valsalva LVOT peak gradient less than 50 mm Hg. |
| Secondary | The proportion of patients at week 30 at least 1 class improvement in NYHA functional classification. | Changes from baseline to week30 in the resting LVOT peak gradient | The proportion of patients at week 30 at least 1 class improvement in NYHA functional classification. |
| Secondary | Changes from baseline to week30 in the resting LVOT peak gradient. | from baseline to week 30 | Changes from baseline to week30 in the resting LVOT peak gradient |
| Secondary | Changes from baseline to week 30 in the KCCQ Clinical Summary Score (KCCQ-CSS) | from baseline to week 30 | Changes from baseline to week 30 in the KCCQ Clinical Summary Score (KCCQ-CSS), |
| Secondary | Changes from baseline to week 30 in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) level. | from baseline to week 30 | Changes from baseline to week 30 in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) level |
| Secondary | Changes from baseline to week 30 in the high-sensitivity cardiac troponin I (hs-cTnI) level. | from baseline to week 30. | Changes from baseline to week 30 in the high-sensitivity cardiac troponin I (hs-cTnI) level. |
| Secondary | Changes from baseline to week 30 left of the ventricular mass index (LVMI) evaluated by CMR imaging. | from baseline to week 30 | Changes from baseline to week 30 left of the ventricular mass index (LVMI) evaluated by CMR imaging. |
| Secondary | Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). | from baseline to week 30 | Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06856265
GET https://conductscience.org/api/trials/v1/NCT06856265/registered